Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sugammadex in ASA Class 3/4 Subjects
NCT03346057Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Primary completion
- Sep 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Dec 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03346057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346057.